Rilotumumab: Difference between revisions
m (Protected "Rilotumumab": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +)) |
||
Line 20: | Line 20: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
==Overview== | ==Overview== | ||
Line 26: | Line 26: | ||
{{humanmonoclonals}} | {{humanmonoclonals}} | ||
[[Category:Monoclonal antibodies]] | [[Category:Monoclonal antibodies]] | ||
[[Category:Cancer treatments]] | [[Category:Cancer treatments]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} |
Latest revision as of 15:45, 20 August 2012
WikiDoc Resources for Rilotumumab |
Articles |
---|
Most recent articles on Rilotumumab Most cited articles on Rilotumumab |
Media |
Powerpoint slides on Rilotumumab |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Rilotumumab at Clinical Trials.gov Clinical Trials on Rilotumumab at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Rilotumumab
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Rilotumumab Discussion groups on Rilotumumab Patient Handouts on Rilotumumab Directions to Hospitals Treating Rilotumumab Risk calculators and risk factors for Rilotumumab
|
Healthcare Provider Resources |
Causes & Risk Factors for Rilotumumab |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Overview
Rilotumumab is a human monoclonal antibody and which it is used to treat cancer.